Bone marrow transplant breakthrough: more donors now possible for blood cancer patients?
NCT ID NCT01203722
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a gentler bone marrow transplant for people with blood cancers who don't have a perfectly matched family donor. Instead, it used donors who are less closely matched, like unrelated volunteers or distant relatives. The goal was to see if this approach could be safe and effective, reducing severe side effects like graft-versus-host disease while helping patients survive longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fludarabine, Cytoxan, Sirolimus, Mycophenolate Mofetil, total body irradiation, and allogeneic blood or marrow transplant
- What this could lead to
- If successful, this approach could expand donor options for blood cancer patients who lack a matched family donor, potentially improving access to life-saving transplants.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 87 participants, so results may not apply to all patients. Risks include severe graft-versus-host disease, infection, and transplant failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231-2410, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI platform aims to unlock Real-World cancer data on a massive scale
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- Could a common arthritis drug shield transplant patients from a dangerous virus?
- New biologic MK-1045 targets Hard-to-Treat blood cancers
- Shorter chemo before transplant may cut severe side effects for blood cancer patients
- Blood test could predict bleeding risk in cancer patients